The ESP club is located in a lane with Tokyo flavor but not too much.

When President Yan Hao walked into the conference room with a serious look, he had nothing to do with the Japanese company president, who had a firm suit.

For a time, reporters couldn't tell whether he was a senior Japanese manager in EPS company or the "student president" in the legend.

However, in his Mandarin, he still has a hint of Jiangsu accent, which makes people feel very friendly.

EPS EVER PROGRESS SYSTEM company is engaged in clinical trial business CRO, CONTRACT RESEARCH ORGANIZATION, essentially a highly specialized outsourcing service, which mainly includes the design and consultation of clinical trial plan and case report form, clinical trial supervision, data management, statistical analysis and statistical analysis report writing.

But unlike professional services such as lawyers or accountants, EPS's target market is very narrow, mainly focused on clinical trials of pharmaceutical companies, with huge profits.

Since its 1991 venture, EPS has been developing steadily until 2001 when it was listed on the JASDAQ (stock code EPS, JASDAQ).

So far, the EPS set up by Yan Hao has been collectivize, and the parent company EPS is responsible for all the business of CRO.

EPS's EPLink company is responsible for the clinical trial site support business (SMO), CyberMedicalNet for the hospital's consulting business.

The software company is mainly responsible for the design and consultation of intelligence processing system.

In addition, EPS has also established the Shanghai Japan new pharmaceutical development Co., Ltd., which is responsible for the whole business of CRO in China, as well as PharmaLinkFHI in the United States, which is responsible for the whole business of CRO in the United States.

The company's performance has reached 5 billion 500 million yen and 522 employees.

The group's performance has reached 8 billion 900 million yen and its staff has reached 992.

In the whole EPS business, CRO business accounts for nearly 70% of the business, while other SMO and non clinical businesses account for 15% of the total.

The listing of EPS has created two first: the first Japanese listed company founded by Chinese students, and the second one is to create an industry: clinical trial outsourcing service industry.

Now the industry has not only been greatly developed, but several competitors have also followed EPS to the market.

According to the latest financial data in June 8th, EPS has a market value of 36 billion 900 million yen, Yan Hao and its relatives held 55.67%. Based on this, it is estimated that Yan Hao is worth about 20 billion 500 million yen or nearly 200 million dollars.

Moreover, EPS's business has increased by 40% in recent years, and Yan Hao's personal wealth is growing.

Yan Hao, an entrepreneur, does not believe that his entrepreneurial history has escaped the imperial edict.

It seems that he is the kind of person who has a pleasant manner.

I arrived in Japan in 1981, the second batch of undergraduate students from the Ministry of education.

79 grade college students, only half a year in University, have trained Japanese for one year.

When he arrived in Japan, Yan Hao was only eighteen and nine years old.

As a public student, his student career is much more relaxed than that of a large number of Chinese students who came to Japan in the late 1980s.

Most importantly, because early in Japan, it soon integrated into the Japanese society, including the acceptance of the culture and value system of Japanese society. This is very important for him to start his own business.

"At that time, there were very few public derivatives. The first group had only one hundred people, and scattered in universities. From Hokkaido to Kyushu, there were only two or three students in every university, surrounded by Japanese classmates, so they soon integrated into them.